Induction of proliferation and augmented cytotoxicity of γδ T lymphocytes by bisphosphonate clodronate [4]

Blood

Volumn 97, Issue 9, 2001, Pages 2917-2918

  Schilbach, Karin ^a   Geiselhart, Andreas ^a   Handgretinger, Rupert ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; INTERLEUKIN 2; OKT 3; PAMIDRONIC ACID; PHYTOHEMAGGLUTININ;

CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; LETTER; LYMPHOCYTE PROLIFERATION; NEUROBLASTOMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0035353168     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.9.2917     Document Type: Letter

References (7)

1. Kunzmann V, Bauer E, Feurle J, Weißinger F, Tony H, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384-392.
2. Schilbach K, Geiselhart A, Wessels J, Niethammer D, Handgretinger R. Human γδ T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells. J Immunother. 2000;23:536-548.
3. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med. 1996;8:334-493.
4. Sansoni P, Passeri G, Fagnoni F, et al. Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Min Res. 1995;10:1719-1725.
5. Kunzmann V, Bauer E, Wilhelm M. g/d T cell stimulation by pamidronate [letter]. N Engl J Med. 1999;340:737-738.
6. Pecherstorfer M, Jilch R, Sauty A, et al. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Min Res. 2000;15:147-154.
7. Blomberg K, Hautala R, Lovgren J, Mukkala VM, Lingqvist C, Akerman K. Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand. J Immunol Meth. 2000;193:199-206.